[January 27, 2016]

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2015 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/jfgfbd/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive adantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview
3. Therapeutics Development
4. Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
5. Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis
6. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies
7. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Investigation by Universities/Institutes
8. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies
13. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Investigation by Universities/Institutes
14. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development

• Celgene Corporation
• CTI (News - Alert) BioPharma Corp.
• Gilead Sciences, Inc.
• Incyte Corporation
• Italfarmaco S.p.A.
• JW Pharmaceutical Corporation
• Nippon Shinyaku Co., Ltd.
• Novartis AG
• Promedior, Inc.

For more information visit http://www.researchandmarkets.com/research/jfgfbd/postpolycythemia

View source version on businesswire.com: http://www.businesswire.com/news/home/20160127005572/en/

[ Back To TMCnet.com's Homepage ]